Comments on: Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

Comments on: Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer https://9krapalm.com/dizal-announces-phase-3-wu-kong28-results-zegfrovy-sunvozertinib-outperforms-platinum-doublet-chemotherapy-in-first-line-egfr-exon-20-insertion-mutation-positive-non-small-cell-lung-cancer/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Fri, 29 May 2026 14:04:39 +0000 hourly 1 https://wordpress.org/?v=6.9.4